13 assets in Juvenile Xanthogranuloma

Therapeutic assets addressing Juvenile Xanthogranuloma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)- Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (53)
Ensartinib Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (53)
Ivosidenib Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (53)
Larotrectinib Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (53)
Olaparib Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (53)
Palbociclib Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (53)
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493 Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (53)
PI3K/MTOR INHIBITOR LY3023414 Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (53)
Selpercatinib Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (53)
Selumetinib Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (53)
Tazemetostat Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (53)
Ulixertinib Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (53)
Vemurafenib Juvenile Xanthogranuloma	National Cancer Institute (NCI)	P2	CCC (52)